Arcus Biosciences (RCUS) Cash from Investing Activities Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -114.28% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 826.39% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -674.01% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -166.24% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -122.45% |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - | 256.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 256.25% |
| Dec 31, 2025 | -456.86% |
| Sep 30, 2025 | 372.41% |
| Jun 30, 2025 | 117.46% |
| Mar 31, 2025 | 118.93% |
| Dec 31, 2024 | 82.14% |
| Sep 30, 2024 | -363.64% |
| Jun 30, 2024 | 142.31% |
| Mar 31, 2024 | -231.01% |
| Dec 31, 2023 | -40.43% |
| Sep 30, 2023 | -52.17% |
| Jun 30, 2023 | 112.09% |
| Mar 31, 2023 | 148.13% |
| Dec 31, 2022 | 150.24% |
| Sep 30, 2022 | 125.96% |
| Jun 30, 2022 | -7,259.51% |
| Mar 31, 2022 | -526.57% |
| Dec 31, 2021 | 13,710.29% |
| Sep 30, 2021 | 77.11% |
| Jun 30, 2021 | 103.45% |
| Mar 31, 2021 | 56.85% |
| Dec 31, 2020 | 101.12% |
| Sep 30, 2020 | -1,374.93% |
| Jun 30, 2020 | -426.45% |
| Mar 31, 2020 | 180.52% |
| Dec 31, 2019 | -582.04% |
| Sep 30, 2019 | 136.44% |
| Jun 30, 2019 | 265.43% |
| Mar 31, 2019 | 186.59% |
| Dec 31, 2018 | 105.97% |
| Sep 30, 2018 | -754.60% |
| Jun 30, 2018 | -397.16% |
| Mar 31, 2018 | 0.01% |